New hope for advanced cancers: first human trial of PMC-309 begins

NCT ID NCT05957081

Recruiting now Disease control Sponsor: PharmAbcine Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug called PMC-309, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose. About 67 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Health
RECRUITING

Melbourne, Victoria, 3004, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital
RECRUITING

Benowa, Queensland, 4217, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ballarat Regional Integrated Cancer Centre (Grampians Health)
RECRUITING

Ballarat, Victoria, 3350, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Cabrini Health Limited
RECRUITING

Malvern, Victoria, 3144, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS